title: Mesalazine-induced psoriasis in patients with inflammatory bowel diseases.
authors.forename: Antonella
authors.initials: A
authors.lastname: Di Cesare
authors.forename: Rosaria
authors.initials: R
authors.lastname: Fidanza
authors.forename: Assunta
authors.initials: A
authors.lastname: Riitano
authors.forename: Maria Concetta
authors.initials: MC
authors.lastname: Fargnoli
authors.forename: Ketty
authors.initials: K
authors.lastname: Peris
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D005121:Extremities; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000009:adverse effects* / Q000627:therapeutic use; D011565:Psoriasis / Q000139:chemically induced* / Q000276:immunology; D060726:Torso
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine